Extracellular Vesicle Linkers for High-Payload Targeted Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery systems, such as antibody-drug conjugates (ADCs), are limited by the number of molecules that can be attached and systemic toxicity, hindering their effectiveness in targeting specific tissues while minimizing overall exposure.
Innovation Solution
Extracellular vesicles (EVs) are engineered with a biologically active molecule linked via a cleavable linker and anchoring moiety, incorporating a cell-penetrating peptide to enhance targeting and minimize systemic exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If antibody-drug conjugates are used to deliver therapeutic compounds, then specific tissue targeting is achieved, but the payload capacity is limited and systemic toxicity increases
Solution Approach 1:
The patent uses extracellular vesicles as intermediary carriers to deliver therapeutic compounds. These EVs serve as a mediator between the therapeutic compound and target cells, enabling higher payload capacity while maintaining selective targeting through surface protein mediation, thus resolving the contradiction between payload capacity and systemic toxicity
Solution Approach 2:
The patent modifies the delivery system by changing from antibody-based conjugates to EV-based carriers, fundamentally altering the parameter of carrier type. This parameter change enables significantly higher payload capacity (multiple molecules per EV) while maintaining targeting specificity, thereby reducing systemic toxicity
2Productivity
If more molecules are attached to the delivery system, then therapeutic efficacy improves, but non-target tissue exposure increases
Solution Approach 1:
EVs act as intelligent intermediaries that can carry multiple therapeutic molecules while using surface proteins as homing devices to guide delivery to specific target tissues. This intermediary approach allows high productivity (multiple molecules per carrier) while preventing non-target tissue exposure through protein-mediated targeting
Solution Approach 2:
The patent applies local quality by concentrating multiple therapeutic molecules within EVs that are specifically localized to target tissues through surface protein expression. This creates a localized high-concentration therapeutic effect at the target site while keeping non-target tissues exposed to minimal or no therapeutic compound
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered EVs provide a higher payload capacity and selective tissue targeting, reducing systemic toxicity and improving therapeutic efficacy.
Implementation Method 1
incorporating a cell-penetrating peptide to enhance targeting
Implementation Method 2
a biologically active molecule linked via a cleavable linker and anchoring moiety
Data Source
AI summary
The present disclosure relates to extracellular vesicles (e.g., exosomes) comprising a biologically active molecule covalently linked to the extracellular vesicle via a cleavable linker comprising a cell penetrating peptide and an anchoring moiety. The extracellular vesicles can be useful as an agent for the prophylaxis or treatment of cancer or other diseases. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat diseases or disorders.